Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Celcuity, Inc. (CELC : NSDQ)

• Company Description    Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular activity driving a patient's cancer and the targeted therapy. Celcuity Inc. is based in Minneapolis, United States. Number of Employees: 39

• Price / Volume Information    Yesterday's Closing Price: $5.70 Daily Weekly Monthly 20 Day Moving Average: 84,777 shares Shares Outstanding: 14.94 (millions) Market Capitalization: $85.14 (millions) Beta: 1.64 52 Week High: $33.01 52 Week Low: $4.81 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.30% -8.35% 12 Week -48.97% -42.65% Year To Date -56.78% -47.21%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 16305 36TH AVENUE NORTH SUITE 100 - MINNEAPOLIS,MN 55446 USA ph: 763-392-0767 fax: - None http://www.celcuity.com

• General Corporate Information    Officers Brian F. Sullivan - Chief Executive Officer and Chairman Vicky Hahne - Chief Financial Officer Lance G. Laing - Chief Science Officer; Vice President and Secretar Richard E. Buller - Director Dave F. Dalvey - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 15102K100 SIC: 8071 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 14.94 Most Recent Split Date: (:1) Beta: 1.64 Market Capitalization: $85.14 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.55 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.82 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.38 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -112.00% vs. Previous Quarter: -17.78% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -59.97 12/31/21 - -57.66 09/30/21 - -68.48 ROA 03/31/22 - -46.26 12/31/21 - -46.09 09/30/21 - -55.23 Current Ratio 03/31/22 - 22.37 12/31/21 - 34.06 09/30/21 - 32.30 Quick Ratio 03/31/22 - 22.37 12/31/21 - 34.06 09/30/21 - 32.30 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 4.12 12/31/21 - 4.61 09/30/21 - 5.00 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.24 12/31/21 - 0.21 09/30/21 - 0.19 Debt-to-Capital 03/31/22 - 19.41 12/31/21 - 17.55 09/30/21 - 16.23

Powered by Zacks Investment Research ©